|Year : 2020 | Volume
| Issue : 4 | Page : 112-115
Effects of montelukast versus inhaled beclomethasone on asthma control and immunoglobulin-E levels in asthmatic children
Afrah A A. Hasan1, Zuhair M Al-Musawi2, Haidar A N. Abood3, Raghdah Maytham Hameed4
1 Department of Pediatrics, Kerbala Teaching Hospital for Pediatrics, Kerbala, Iraq
2 Department of Pediatrics, University of Kerbala, Kerbala, Iraq
3 Department of Pharmacology, University of Kerbala, Kerbala, Iraq
4 Department of Medical Microbiology, University of Kerbala, Kerbala, Iraq
|Date of Submission||16-Jul-2020|
|Date of Acceptance||04-Aug-2020|
|Date of Web Publication||9-Oct-2020|
Miss. Raghdah Maytham Hameed
Department of Medical Microbiology, University of Kerbala, Kerbala
Source of Support: None, Conflict of Interest: None
Background: Beclomethasone dipropionate inhaler is a corticosteroid medication used as the controller of persistent asthma. Montelukast is a leukotriene receptor antagonist used as the second-line in controlling the symptoms of the asthmatic child. Objective: The objective of this study is to determine the comparison between the effects of beclomethasone dipropionate inhaler and montelukast on the total serum level of immunoglobulin E (IgE) and childhood asthma control test (C-ACT) in asthmatic children. Patients and Methods: A randomized clinical trial was done in Kerbala Teaching Hospital of pediatric from August 2014 to the end of October 2015, 97 patients were collected from asthma outpatient clinic aged 4 to 11 years with mild persistent asthma and randomly divided into beclomethasone group (51 patients) and montelukast group (46 patients), the total serum IgE was done before the initiation of treatment, and another reading was done after 3 months. The score of symptoms control was evaluated by C-ACT after 1 month of treatment, and another evaluation was done 2 months later. Results: There was a significant reduction in total serum IgE level (21% for montelukast group and 27% for beclomethasone group) after 3 months of treatment compared to baseline IgE, and there was significant improvement in childhood C-ACT scores (16% for montelukast group and 24% for beclomethasone group) after 3 months of treatment compared to the 1st month of treatment. There was a significant improvement in the beclomethasone group compared to the montelukast group after 3 months of treatment. Conclusions: Both beclomethasone and montelukast are effective controllers for asthma symptoms and reducing the total serum IgE level. Beclomethasone is better than montelukast in improving C-ACT scores.
Keywords: Beclomethasone dipropionate, bronchial asthma, montelukast
|How to cite this article:|
A. Hasan AA, Al-Musawi ZM, N. Abood HA, Hameed RM. Effects of montelukast versus inhaled beclomethasone on asthma control and immunoglobulin-E levels in asthmatic children. Matrix Sci Med 2020;4:112-5
|How to cite this URL:|
A. Hasan AA, Al-Musawi ZM, N. Abood HA, Hameed RM. Effects of montelukast versus inhaled beclomethasone on asthma control and immunoglobulin-E levels in asthmatic children. Matrix Sci Med [serial online] 2020 [cited 2021 Jan 25];4:112-5. Available from: https://www.matrixscimed.org/text.asp?2020/4/4/112/297635
| Introduction|| |
Asthma is a chronic inflammatory disorder of the airways in which many cells and cellular elements play a role, in particular, mast cells, eosinophils, T-lymphocytes, macrophages, neutrophils, and epithelial cells. In susceptible individuals, this inflammation causes recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, particularly at night or in the early morning. These episodes are usually associated with widespread, but variable airflow obstruction that is often reversible either spontaneously or with treatment. The inflammation also causes an associated increase in the existing bronchial hyperresponsiveness to a variety of stimuli.
Chronic airway inflammation is recognized as an important component of the disease in even the most mildly symptomatic patients. The recognition that chronic inflammatory changes begin at the onset of asthma symptoms has resulted in the increasing use of anti-inflammatory therapy. Inhaled corticosteroids (ICSs) are the most effective controller therapy for asthma in children of all ages. Corticosteroids are the most potent anti-inflammatory drugs currently available for the treatment of asthma. Leukotriene modifiers include leukotriene receptor antagonists (LTRA) and a 5-lipoxygenase inhibitor that are available as oral controller drugs for the treatment of pediatric asthma.
Immunoglobulin E (IgE) is involved in allergic inflammation, especially in early-phase response, but it also involved in late-phase allergic response and the development of chronic allergic diseases. In allergic asthma, total serum IgE level can be used as a biomarker for monitoring response to therapy. The childhood asthma control test (C-ACT) provides valuable information regarding asthma control and can discriminate children with different control levels of the disease. Several studies used the C-ACT to estimate asthma control in children. The test was also used by pharmacological studies to evaluate the responses to drug therapy. These make it necessary to examine the effects of beclomethasone dipropionate inhaler and montelukast on the total serum level of IgE and C-ACT in asthmatic children.
Aim of study
The aim of this study is to determine the comparison between the effects of beclomethasone dipropionate inhaler and montelukast on the total serum level of IgE and C-ACT in asthmatic children.
The study protocol was approved by the Ethical Committee in the Iraqi Council for Medical Specialization on January 28, 2015, approval number 482. In addition, verbal approval was obtained from the patients and/or their parents before taking the sample.
| Patients and Methods|| |
Our study was done in Kerbala Teaching Hospital of Pediatrics from August 1, 2014, to the end of October 2015, and our patients were collected from asthma outpatient clinic of the hospital.
A randomized clinical study was done on 104 patients, seven of them did not complete the study (because of lack of contact), and assessment of asthma severity was done for each patient.
Mild persistent asthmatic patients with age ranged from 4 to 11 years were included in the study.
Patients on controller therapy, patients who received systemic corticosteroids therapy 1 week before this study, and patients with other chronic diseases were excluded from the study.
Our study included 97 patients randomly allocated into two groups:
- Beclomethsone group: This group included 51 patients who received beclomethasone inhaler (500 microgram (mcg)/day) through spacer device according to the age (with or without face mask), we explained to the patients the procedure of using this inhaler with spacer and number of puffs/day, (dose: 250 mcg twice daily)
- Montelukast group: This group included 46 patients, montelukast chewable tablet was given at night, the dose for patients <5 years is 4 mg and for patients aged 5 years or more is 5 mg.
Patients assessment and follow-up
Included the following:
- IgE assessment: Determination of total serum IgE level was performed by TOSOH AIA-360 Analyzer (an automated immunoassay analyzer) using a ready-made kit (ST AIA-PACK IgE II) for this purpose
- C-ACT: Asthma control test consists of 7 questions, 2 part questionnaire, with one part to be completed by the child (four questions referring to the present condition) and the other part to be answered by the parents (three questions referring to the past 4 weeks). An interview was done with each patient and parent separately. It was translated to the Arabic language, and then, the score was calculated for each patient.
Data were introduced into the Statistical Package for the Social Sciences (SPSS) software version 21 (Graph Pad Software, San Diego, California, USA) to do statistical analysis. The results were expressed as mean ± standard deviation. Comparisons between two means were performed using the t-test. The Chi-square test was used to compare between two categorical variables. P > 0.05 was considered to indicate nonstatistical significance while statistically significant if P < 0.01.
| Results|| |
Ninety-seven patients (their ages between 4 and 11 years) completed the study, 51 patients were received inhaled beclomethasone, and 46 patients received montelukast for 3 months. Seven patients (3 from beclomethasone group and 4 from montelukast group) did not complete the study.
Baseline characteristics for the patients who completed the study show no significant difference in both groups [Table 1].
At the beginning of the study, serum levels of total IgE did not differ among the beclomethasone and montelukast groups (P > 0.05), whereas after 3 months of treatment, there was highly significant reduction (P < 0.01) in total serum IgE levels for patients treated with montelukast or inhaled beclomethasone (21% and 27% respectively), compared to baseline levels. There was no significant difference (P > 0.05) in total serum IgE levels between patients in montelukast and beclomethasone groups after treatment [as shown in [Table 2].
|Table 2: Effects of treatment with inhaled beclomethasone and montelukast on total serum IgE levels in children with asthma|
Click here to view
At the end of the 1st month of treatment, there was no significant difference (P > 0.05) in C-ACT scores between patients in montelukast and beclomethasone treatment groups. While, at the end of 3rd month of treatment, there was a highly significant increase (P < 0.01) in the C-ACT score for patients treated with montelukast and beclomethasone (16% and 24% respectively), compared to score after 1 month. There was a highly significant difference (P < 0.01) in C-ACT between patients in montelukast and beclomethasone groups after treatment [as presented in [Table 3].
|Table 3: Effects of treatment with beclomethasone and montelukast on childhood asthma control test scores in children with asthma during the treatment period|
Click here to view
| Discussion|| |
Children with persistent asthma are in need of controller therapy, currently ICSs had been widely recommended as the favorable treatment in patients with persistent asthma, including asthmatic children of different ages. The LTRAs considered as a successful substitute for the management of persistent asthma in children. Montelukast reported to be the first LTRA that approved by the food and drug administration to be used in young children with asthma.
The IgE is confirmed to play a fundamental role in allergic immune response; hence, the reduction of total and specific IgE level has been attractive goal in the management of allergic diseases.
The current study aimed to assess the effect of montelukast versus beclomethasone on the total serum IgE level and asthma control test in children aged 4–11 years, the age and gender distribution was not significantly different between both treatment groups (beclomethasone and montelukast) which indicated adequate randomization and assignment of patients to receive the medication.
Regarding the effects of treatment with montelukast and inhaled beclomethasone on the total serum IgE level in asthmatic children, the present study found that both treatments had significantly reduced the levels of total serum IgE compared to its level at baseline. The mean serum level of total IgE was significantly reduced to 27% in beclomethasone group, and significant reduction to 21% in montelukast group. However, despite the reduction was larger with inhaled beclomethasone than montelukast, the differences in the mean total serum IgE level were statistically insignificant between both groups neither at baseline nor after 3 months, these findings indicated that the effect of montelukast on the total serum IgE level was approximate that of inhaled beclomethasone. These findings agreed that reported in previous studies which compared the effect of these two drugs on the total serum IgE level, In an Italian study, Scaparrotta reported that ICSs and montelukast significantly reduced the serum levels of total and specific IgE in asthmatic children aged 5–11 years. Similar findings were also reported in an Iranian study was conducted by Razi and Mossave who found a significant improvement in the symptoms and reduction in the circulating total and allergen specific IgE level in asthmatic children aged 6–12 years.
The current study found a significant improvement in the C-ACT scores after 3 months of treatment (16% improvement in montelukast group and 24% improvement in beclomethasone group) compared to the 1st month of treatment, on the other hand, a statistically significant difference between both groups had been found at 3 months, where the mean C-ACT score was significantly higher in beclomethasone group than in montelukast group [Table 3], In an Egyptian study, Ahmed et al. reported that both inhaled beclomethasone (the dose used was 600 mcg) and montelukast (the dose used was 5 mg) improved asthma symptoms score after 3 and 6 months of treatment and found that inhaled beclomethasone superior to montelukast at this point.
At another point of our study, there was parallel improvement in asthma control test in the patient who had reduced total serum IgE level after treatment in both groups, this indicates that the treatment which reduce total serum level of IgE would improve asthma control by improvement of IgE allergic reactions as reported in Ahmed et al.
| Conclusions|| |
- Both chewable montelukast and inhaled beclomethasone had significantly improved asthma control after 3 months of treatment, and both drugs were effective in reducing the total serum IgE level in asthmatic children
- Inhaled beclomethasone at dose of 500 mcg/day was significantly better than montelukast in improving asthma control.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Guill MF. Asthma update: Epidemiology and pathophysiology. Pediatr Rev 2004;25:299-305.
O'Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet 2006;368:794-803.
Faul JL, Demers EA, Burke CM, Poulter LW. Alterations in airway inflammation and lung function during corticosteroid therapy for atopic asthma. Chest 2002;121:1414-20.
Bisgaard H. Leukotriene modifiers in pediatric asthma management. Pediatrics 2001;107:381-90.
Rosenwasser LJ. Mechanisms of IgE Inflammation. Curr Allergy Asthma Rep 2011;11:178-83.
Lang JE, Blake KV. Role of biomarkers in understanding and treating children with asthma: Towards personalized care. Pharmgenomics Pers Med 2013;6:73-84.
Yavuz ST, Civelek E, Sahiner UM, Buyuktiryaki AB, Tuncer A, Karabulut E, et al
. Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement. Ann Allergy Asthma Immunol 2012;109:36-40.
Liu AH, Zeiger RS, Sorkness CA, Ostrom NK, Chipps BE, Rosa K, et al
. The childhood asthma control test: Retrospective determination and clinical validation of a cut point to identify children with very poorly controlled asthma. J Allergy Clin Immunol 2010;126:267-73, 273.e1.
Scaparrotta A, Di Pillo S, Attanasi M, Rapino D, Cingolani A, Consilvio NP, et al
. Montelukast versus inhaled corticosteroids in the management of pediatric mild persistent asthma. Multidiscip Respir Med 2012;7:13.
Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 2001;164:S1-5.
Razi E, Moosavi GA. Serum total IgE levels and total eosinophil counts relationship with treatment response in patient with asthma. J Bras Pneumol puplicaco of da Soc Bras Pneumol e Tisilogia 2010;36: 23-8.
Ahmed AR, Shaheen AM, Shaheen FA. The effect of beclomethasone inhalation and oral montelukast sodium. On serum IgE level and clinical parameters in asthmatic children. Alexa J Pediatr 2005;19:341-6.
[Table 1], [Table 2], [Table 3]